Prostate Cancer | Disease Landscape and Forecast | G7 | 2022

Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment algorithms for nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Some patients with mCRPC are receiving triple combinations of current therapies. The dynamic late-phase pipeline mostly focuses on mCRPC and comprises a plethora of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, Roche’s ipatasertib, AstraZeneca’s capivasertib) and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s 177Lu-PSMA-617, Telix’s 77Lu-DOTA-rosopatamab, POINT Biopharma’s 177Lu-PNT2002). These agents will likely contribute to robust market growth over the 2021-2031 forecast period.

QUESTIONS ANSWERED

  • What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
  • What are the key drivers and constraints in the prostate cancer therapy market, and how will the major markets evolve over the 10-year forecast period?
  • What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will their positioning and uptake in the market be?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report